A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Tasmar Overdose, Contraindications and Information - Tolcapone
Tasmar Overdose, Contraindications and Information - Tolcapone
OVERDOSE
The highest dose of tolcapone administered to humans was 800 mg t.i.d.,
with and without levodopa/carbidopa coadministration. This was in a 1-week
study in elderly, healthy volunteers. The peak plasma concentrations of
tolcapone at this dose were on average 30 mg/mL (compared to 3 mcg/mL
and 6 mcg/mL with 100 mg
and 200 mg tolcapone, respectively). Nausea, vomiting and dizziness were
observed, particularly in combination with levodopa/carbidopa.
The threshold for the lethal plasma concentration for tolcapone based
on animal data is >100 mg/mL.
Respiratory difficulties were observed in rats at high oral (gavage) and
intravenous doses and in dogs with rapidly injected intravenous doses.
Management of Overdose: Hospitalization is advised. General
supportive care is indicated. Based on the physicochemical properties
of the compound, hemodialysis is unlikely to be of benefit.
CONTRAINDICATIONS
TASMAR tablets are contraindicated in patients with liver disease, in
patients who were withdrawn from TASMAR because of evidence of TASMAR-induced
hepatocellular injury or who have demonstrated hypersensitivity to the
drug or its ingredients.
TASMAR is also contraindicated in patients with a history of non-traumatic
rhabdomyolysis or hyperpyrexia and confusion possibly related to medication
(see PRECAUTIONS: Events Reported
With Dopaminergic Therapy).
top
